ࡱ> LK( / 0DArialNew RomanllC b0DWingdingsRomanllC b0 DTimes New RomanllC b0@ .  @n?" dd@  @@`` 8&@ !"#$% 0AA@3ʚ;ʚ;g4RdRdlF b0ppp@ <4dddd8i0lC  80___PPT10  Literature Review}Peter R. McNally, DO, FACP, FACG University of Colorado School of Medicine Center for Human Simulation Aurora, Colorado 80045~~ qScarpellini E, Gabrielli M, Lauritano C, Lupascu A, Merra G, Cammarota G, Cazzato IA, Gasbarrini G, Gasbarrini A.rr$High Dose Rifaximin for Treatment of Small Intestinal Bacterial Overgrowth. Alimentary Pharmacology & Therapeutics. 2007;25:781-786.    IntroductionSmall intestinal bacterial overgrowth (SIBO) is a burgeoning field of study in the etiology of Irritable Bowel Syndrome (IBS). Many antibiotics have been examined in the treatment of SIBO. (Lin HC. JAMA 2004;292:852-858.) Metrinodizole Ciprofloxacin Tetracycline Neomycin Rifaximin Rifaximin is a non absorbed, intra-luminal antibiotic that appears to have the best efficacy in treatment of this disorder.VZ<Z|Z;{AimScarpellini et al, conducted a dose ranging trial of Rifaximin at doses of 1600 mg/day vs. 1200 mg/day to assess efficacy, safety and tolerability in the treatment of SIBO.  Study Design:O80 consecutive pts with SIBO were enrolled. Diagnosis of SIBO based upon clinical history and positive Glucose Breath Test (GBT), defined as > 20 ppm rise in H2/CH4. Treatment randomized to 7- days of Rifaximin 1600 mg/d (Group 1) or 1200 mg/d (Group 2). Objective measurements: GBT 1 month after treatment Compliance Side effectsl4  w4 ResultsDrop outs: 1 patient in group 1 GBT normalization Group 1 > Group 2 (80% vs. 58%; p < 0.05 ITT model) and (82% vs. 61%; p<0.05 PP). Compliance: NS difference Side effect profile: NS difference. <4RA4RA  ConclusionsThis study demonstrates that Rifaximin 1600 mg/d had significantly higher efficacy for treatment of SIBO than 1200mg/d. Compliance rates and side effects with Rifaximin 1600 mg/d compared favorably with 1200 mg/d.Z Reviewer Comments-This is a simple dose ranging trial to evaluate efficacy, compliance and safety of Rifaximin at 1600 mg/d vs. 1200 mg/day. It is likely that future studies examining treatment of IBS patients with SIBO will be conducted using this higher dose of Rifaximin that appears to be safe and more effective..Z./      0` ̙33` ` ff3333f` 333MMM` f` f` 3>?" dU,x? " _d  " @` n?" dd@   @@``PR    @ ` ` p>> @P\(  P P  `@ xaxa1 ?P   X Click to edit Master title style!!   P Z xaxa1 ?   X Click to edit Master text styles!!   P  `{ 1?Ud *"       hh88 P  `~ 1?r f    hh88\ P 63޽h ?"` Oa( Vienna980 zr@ (    0G  P     P*    0L       R*  d  c $ ?     0O   0   RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  6U  _P    P*    6t  _    R*  H  0޽h ? 3380___PPT10.`{- 0 PT<(  T~ T s * Pn   ~ T s *lȊ P@p    H T 0޽h ? 33___PPT10i.8dW+D='  = @B +H0 _WP(  x  c $- PP   x  c $- P0P      0t/  g WValencia, Spain,|( _H  0޽h ? Oa(___PPT10i.e+D='  = @B +  0 d;(  dx d c $ P   x d c $T' P    d Z@ xaxao ?p y;Scarpellini E, et al. Aliment Pharm Ther. 2007;25:781-786."< ;H d 0޽h ? Oa(___PPT10i. w;+D='  = @B +  0 l<(  lx l c $<ޱ PP   x l c $߱ P    l Z xaxao ? z<Scarpellini E, et al. Aliment Pharm Ther. 2007;25:781-786. "= ;H l 0޽h ? Oa(___PPT10i.p }<+D='  = @B +  0 t<(  tx t c $ PP   x t c $ P@    t Z, xaxao ? z<Scarpellini E, et al. Aliment Pharm Ther. 2007;25:781-786. "= ;H t 0޽h ? Oa(___PPT10i.@P1+D='  = @B +  0 |:(  |x | c $T PP   x | c $| P    | Zx xaxao ?P x:Scarpellini E, et al. Aliment Pharm Ther. 2007;25:781-86."; :H | 0޽h ? Oa(___PPT10i.02+D='  = @B + 0 :(  x  c $ PP   x  c $ P     Z4t xaxao ? x:Scarpellini E, et al. Aliment Pharm Ther. 2007;25:781-86."; :H  0޽h ? Oa(___PPT10i.`g+D='  = @B + 0 0:(  x  c $R PP   x  c $S P     ZT xaxao ?P x:Scarpellini E, et al. Aliment Pharm Ther. 2007;25:781-86."; :H  0޽h ? Oa(___PPT10i.ߺ+D='  = @B +0 `X((  X^ X S     X c $X  0    H X 0޽h ? 3380___PPT10. 0 h((  h^ h S     h c $j  0    H h 0޽h ? 3380___PPT10. Ph0 p((  p^ p S     p c $f  0    H p 0޽h ? 3380___PPT10. 0ަ0 x((  x^ x S     x c $\  0    H x 0޽h ? 3380___PPT10. 0 ((  ^  S      c $  0    H  0޽h ? 3380___PPT10. 0  ((  ^  S      c $h  0    H  0޽h ? 3380___PPT10. .0 @((  ^  S      c $0  0    H  0޽h ? 3380___PPT10.@%˛rT@pr p_&)-514k8<p&>F@fBDFH#J1Oh+'0) `h   Literature ReviewPeter R. McNallySusan McNevin5Microsoft Office PowerPoint@х%@q#@J퉸nG(g  AE  y---$----$----$----$----$----$----$-- --$-- !--$ -- $--$ -- &--$ -- )--$ -- +--$ -- ,--$  -- .--$-- 0--$--2--$--4--$--7--$--9--$--;--$--=--$--?--$--@--$--B--$--D--$--G--$--I--$--K--$--M--$--O--$--Q--$ --S--$ !! --V--$!""!!--X--$"##""--Z--$#$$##--\--$$%%$$--^--$%&&%%--`--$&''&&--b--$'((''--d--$())((--f--$)**))--h--$*++**--j--$+,,++--l--$,--,,--n--$-..----p--$.//..--r--$/00//--t--$01100-- v--$12211-- x--$23322--!z--$34433--"|--$45544--#}--$56655--#--$67766--#--$78877--#--$89988--$--$9::99--$--$:;;::--%--$;<<;;--&--$<==<<--'--$=>>==--'--$>??>>--'--$?@@??--(--$@AA@@--(--$ABBAA--)--$BCCBB--)--$CDDCC--*--$DEEDD--*--$EFFEE--*--$FGGFF--*--$GHHGG--+--$HIIHH--+--$IJJII--,--$JKKJJ--,--$KLLKK--,--$LMMLL-----$MNNMM-----$NOONN-----$OPPOO-----$PQQPP-----$QRRQQ-----$RSSRR--.--$SUUSS--.--$UVVUU--.--$VWWVV--/--$WYYWW--/--$YZZYY--0--$Z[[ZZ--0--$[\\[[--0--$\^^\\--1--$^``^^--1--$`bb``--1--$bddbb--2--$dffdd--2--$fhhff--2--$hiihh--2--$immii--2--$moomm--2--$ouuoo--3--$uxxuu---'@Arial-.  2 w1..  2 v1."SystemH:-@Arial-. !2 %)Literature Review8.. !2 $(Literature Review8.-@Arial-. 72 >! Peter R. McNally, DO, FACP, FACG.. 72 = Peter R. McNally, DO, FACP, FACG.-@Arial-. E2 E)University of Colorado School of Medicine.. E2 D)University of Colorado School of Medicine.-@Arial-. 02 N)Center for Human Simulation .. 02 M(Center for Human Simulation .-@Arial-. (2 V1Aurora, Colorado 80045.. (2 U0Aurora, Colorado 80045.-՜.+,0    JOn-screen ShowMcNallyColorado, LLCfK4  Arial WingdingsTimes New Roman Vienna98Literature ReviewrScarpellini E, Gabrielli M, Lauritano C, Lupascu A, Merra G, Cammarota G, Cazzato IA, Gasbarrini G, Gasbarrini A. IntroductionAimStudy Design:Results ConclusionsReviewer Comments  Fonts UsedDesign Template Slide Titles%_BK Susan McNevinSusan McNevin  !"#$%'()*+,-./0123456789:<=>?@ABDEFGHIJMRoot EntrydO)Current UserCSummaryInformation(&)PowerPoint Document(fKDocumentSummaryInformation8;